Banco Bilbao Vizcaya Argentaria S.A. Raises Stake in DexCom, Inc. (NASDAQ:DXCM)

Banco Bilbao Vizcaya Argentaria S.A. boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 20.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,014 shares of the medical device company’s stock after buying an additional 3,547 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in DexCom were worth $1,635,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of DXCM. Virtu Financial LLC acquired a new position in DexCom in the third quarter valued at approximately $1,020,000. Pine Valley Investments Ltd Liability Co lifted its holdings in DexCom by 59.2% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock valued at $381,000 after acquiring an additional 2,111 shares during the period. World Investment Advisors LLC acquired a new position in DexCom in the third quarter valued at approximately $2,351,000. Wilmington Savings Fund Society FSB acquired a new position in DexCom in the third quarter valued at approximately $381,000. Finally, Tidal Investments LLC lifted its holdings in DexCom by 68.0% in the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock valued at $2,463,000 after acquiring an additional 14,872 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.32% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on DXCM shares. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.00.

DexCom Stock Up 1.2 %

Shares of NASDAQ:DXCM opened at $71.66 on Monday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $73.09 and a two-hundred day moving average of $76.73. The stock has a market cap of $28.10 billion, a P/E ratio of 50.11, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.26.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.